Alendronate in Juvenile Osteoporosis
Completed
Conditions studied: Juvenile Osteoporosis, Low Bone Density, Fractures
In brief
The investigators earlier have shown that treatment of patients with juvenile osteoporosis with alendronate (Fosamax) for 12 months increased the bone density without side effects. In an open label study (10 patients) and double blind, crossover study (11 patients alendronate and 11 patients placebo), the investigators have further observed that alendronate increased the bone density significantly where as placebo (calcium and vitamin D) increased only minimally. These trials were completed. Thus, a post study is designed to evaluate the current status of the bone density and fractures after the patients discontinued the alendronate treatment. No treatment is involved.
Key facts
- Study ID
- NCT00920075
- Run by
- Medical University of South Carolina
- People needed
- 11
- Starts
- 2009-07-01
- Expected to finish
- 2010-10-01
- Last updated by the study team
- 2018-07-11
Who can join
Age: 8 and older, up to 21. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Participated in our earlier clinical study;
- Completed the earlier open label or double blind study;
- Availability to participate in the post study;
- Male and female children who have earlier participated in our clinical trial; AND
- Parental consent (and patient assent after age 12 years) to participate in the study. Participant's consent for those who have completed 18 years of age and above at the time of clinic visit.
You may not qualify if…
- Not participated in our earlier clinical study;
- Not completed our earlier trials; OR
- Pregnancy.
Where it is running
- Medical University of South Carolina — Charleston, South Carolina, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.